On Monday 9 December, the European Commission, through the Health Emergency Preparedness and Response Authority (HERA), signed a €20 million HERA Invest agreement with the Danish biotechnology company SNIPR Biome.
With the support of the European Investment Bank (EIB), this agreement aims to advance the development of innovative therapies that specifically target infections resistant to traditional antibiotics.
This is an important step in the fight against antimicrobial resistance, one...